Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.

Dix DB, Fernandez CV, Chi YY, Mullen EA, Geller JI, Gratias EJ, Khanna G, Kalapurakal JA, Perlman EJ, Seibel NL, Ehrlich PF, Malogolowkin M, Anderson J, Gastier-Foster J, Shamberger RC, Kim Y, Grundy PE, Dome JS; AREN0532 and AREN0533 study committees.

J Clin Oncol. 2019 Aug 26:JCO1801972. doi: 10.1200/JCO.18.01972. [Epub ahead of print]

PMID:
31449468
2.

National Cancer Institute Basket/Umbrella Clinical Trials: MATCH, LungMAP, and Beyond.

Chen AP, Eljanne M, Harris L, Malik S, Seibel NL.

Cancer J. 2019 Jul/Aug;25(4):272-281. doi: 10.1097/PPO.0000000000000389.

PMID:
31335391
3.

Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group.

Steinherz PG, Seibel NL, Sather H, Ji L, Xu X, Devidas M, Gaynon PS.

Leukemia. 2019 Sep;33(9):2144-2154. doi: 10.1038/s41375-019-0422-z. Epub 2019 Feb 28.

4.

Impact of cyclophosphamide and etoposide on outcome of clear cell sarcoma of the kidney treated on the National Wilms Tumor Study-5 (NWTS-5).

Seibel NL, Chi YY, Perlman EJ, Tian J, Sun J, Anderson JR, Ritchey ML, Thomas PR, Miser J, Kalapurakal JA, Grundy PE, Green DM.

Pediatr Blood Cancer. 2019 Jan;66(1):e27450. doi: 10.1002/pbc.27450. Epub 2018 Sep 25.

PMID:
30255545
5.

Reply to D.M. Green.

Dix DB, Seibel NL, Chi YY, Khanna G, Mullen EA, Geller JI, Kalapurakal JA, Ehrlich PF, Malogolowkin MH, Fernandez CV, Dome JS.

J Clin Oncol. 2018 Sep 13:JCO1800659. doi: 10.1200/JCO.18.00659. [Epub ahead of print] No abstract available.

PMID:
30212299
6.

Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study.

Dix DB, Seibel NL, Chi YY, Khanna G, Gratias E, Anderson JR, Mullen EA, Geller JI, Kalapurakal JA, Paulino AC, Perlman EJ, Ehrlich PF, Malogolowkin M, Gastier-Foster JM, Wagner E, Grundy PE, Fernandez CV, Dome JS.

J Clin Oncol. 2018 Jun 1;36(16):1564-1570. doi: 10.1200/JCO.2017.77.1931. Epub 2018 Apr 16.

7.

Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.

Chandrasekar P, Sirohi B, Seibel NL, Hsu JW, Azie N, Wu C, Ruhnke M.

Mycoses. 2018 May;61(5):331-336. doi: 10.1111/myc.12748. Epub 2018 Feb 2.

PMID:
29364548
8.

Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.

Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D.

J Clin Oncol. 2017 Aug 1;35(22):2580-2587. doi: 10.1200/JCO.2016.72.0177. Epub 2017 May 4. Review.

9.

Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.

Allen CE, Laetsch TW, Mody R, Irwin MS, Lim MS, Adamson PC, Seibel NL, Parsons DW, Cho YJ, Janeway K; Pediatric MATCH Target and Agent Prioritization Committee.

J Natl Cancer Inst. 2017 May 1;109(5). doi: 10.1093/jnci/djw274.

10.

Pediatric oncology enters an era of precision medicine.

Seibel NL, Janeway K, Allen CE, Chi SN, Cho YJ, Glade Bender JL, Kim A, Laetsch TW, Irwin MS, Takebe N, Tricoli JV, Parsons DW.

Curr Probl Cancer. 2017 May - Jun;41(3):194-200. doi: 10.1016/j.currproblcancer.2017.01.002. Epub 2017 Feb 1.

PMID:
28343740
11.

Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.

Seibel NL, Shad AT, Bekersky I, Groll AH, Gonzalez C, Wood LV, Jarosinski P, Buell D, Hope WW, Walsh TJ.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01477-16. doi: 10.1128/AAC.01477-16. Print 2017 Feb.

12.

Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children.

Lestner JM, Groll AH, Aljayyoussi G, Seibel NL, Shad A, Gonzalez C, Wood LV, Jarosinski PF, Walsh TJ, Hope WW.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7340-7346. doi: 10.1128/AAC.01427-16. Print 2016 Dec.

13.

Low Enrollment of Adolescents and Young Adults Onto Cancer Trials: Insights From the Community Clinical Oncology Program.

Roth ME, O'Mara AM, Seibel NL, Dickens DS, Langevin AM, Pollock BH, Freyer DR.

J Oncol Pract. 2016 Apr;12(4):e388-95. doi: 10.1200/JOP.2015.009084. Epub 2016 Mar 29.

14.

Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma.

Tricoli JV, Blair DG, Anders CK, Bleyer WA, Boardman LA, Khan J, Kummar S, Hayes-Lattin B, Hunger SP, Merchant M, Seibel NL, Thurin M, Willman CL.

Cancer. 2016 Apr 1;122(7):1017-28. doi: 10.1002/cncr.29871. Epub 2016 Feb 5. Review.

15.

Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future.

Smith AW, Seibel NL, Lewis DR, Albritton KH, Blair DF, Blanke CD, Bleyer WA, Freyer DR, Geiger AM, Hayes-Lattin B, Tricoli JV, Wagner LI, Zebrack BJ.

Cancer. 2016 Apr 1;122(7):988-99. doi: 10.1002/cncr.29870. Epub 2016 Feb 5. Review.

16.

Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.

Ko RH, Jones TL, Radvinsky D, Robison N, Gaynon PS, Panosyan EH, Avramis IA, Avramis VI, Rubin J, Ettinger LJ, Seibel NL, Dhall G.

Cancer. 2015 Dec 1;121(23):4205-11. doi: 10.1002/cncr.29641. Epub 2015 Aug 26.

17.

Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.

Meany HJ, Seibel NL, Krailo M, Villaluna D, Chen Z, Gaynon P, Neglia JP, Park JR, Hutchinson R, Sato JK, Wells RJ, Woods WG, Reaman G.

J Immunother. 2015 Sep;38(7):299-305. doi: 10.1097/CJI.0000000000000088.

18.

Comparative Toxicity by Sex Among Children Treated for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.

Meeske KA, Ji L, Freyer DR, Gaynon P, Ruccione K, Butturini A, Avramis VI, Siegel S, Matloub Y, Seibel NL, Sposto R.

Pediatr Blood Cancer. 2015 Dec;62(12):2140-9. doi: 10.1002/pbc.25628. Epub 2015 Jul 14.

19.

Psychosocial and Neurocognitive Outcomes in Adult Survivors of Adolescent and Early Young Adult Cancer: A Report From the Childhood Cancer Survivor Study.

Prasad PK, Hardy KK, Zhang N, Edelstein K, Srivastava D, Zeltzer L, Stovall M, Seibel NL, Leisenring W, Armstrong GT, Robison LL, Krull K.

J Clin Oncol. 2015 Aug 10;33(23):2545-52. doi: 10.1200/JCO.2014.57.7528. Epub 2015 Jul 6.

20.

Are we missing an opportunity for cancer prevention? Human papillomavirus vaccination for survivors of pediatric and young adult cancers.

Temkin SM, Seibel NL.

Cancer. 2015 Oct 1;121(19):3395-402. doi: 10.1002/cncr.29515. Epub 2015 Jun 25. Review.

21.

US trends in survival disparities among adolescents and young adults with non-Hodgkin lymphoma.

Kent EE, Breen N, Lewis DR, de Moor JS, Smith AW, Seibel NL.

Cancer Causes Control. 2015 Aug;26(8):1153-62. doi: 10.1007/s10552-015-0609-1. Epub 2015 Jun 18.

22.

The Clinical Trials Gap for Adolescents and Young Adults with Cancer: Recent Progress and Conceptual Framework for Continued Research.

Freyer DR, Seibel NL.

Curr Pediatr Rep. 2015 Jun;3(2):137-145. doi: 10.1007/s40124-015-0075-y. Epub 2015 Feb 18.

23.

Identifying and addressing the needs of adolescents and young adults with cancer: summary of an Institute of Medicine workshop.

Nass SJ, Beaupin LK, Demark-Wahnefried W, Fasciano K, Ganz PA, Hayes-Lattin B, Hudson MM, Nevidjon B, Oeffinger KC, Rechis R, Richardson LC, Seibel NL, Smith AW.

Oncologist. 2015 Feb;20(2):186-95. doi: 10.1634/theoncologist.2014-0265. Epub 2015 Jan 7. Review.

24.

Adolescent and young adult cancer survival.

Lewis DR, Seibel NL, Smith AW, Stedman MR.

J Natl Cancer Inst Monogr. 2014 Nov;2014(49):228-35. doi: 10.1093/jncimonographs/lgu019.

25.

Weight change during childhood acute lymphoblastic leukemia induction therapy predicts obesity: a report from the Children's Oncology Group.

Withycombe JS, Smith LM, Meza JL, Merkle C, Faulkner MS, Ritter L, Seibel NL, Moore K.

Pediatr Blood Cancer. 2015 Mar;62(3):434-9. doi: 10.1002/pbc.25316. Epub 2014 Nov 18.

27.

Use of appropriate initial treatment among adolescents and young adults with cancer.

Potosky AL, Harlan LC, Albritton K, Cress RD, Friedman DL, Hamilton AS, Kato I, Keegan TH, Keel G, Schwartz SM, Seibel NL, Shnorhavorian M, West MM, Wu XC; AYA HOPE Study Collaborative Group.

J Natl Cancer Inst. 2014 Oct 9;106(11). pii: dju300. doi: 10.1093/jnci/dju300. Print 2014 Nov.

28.

Declining childhood and adolescent cancer mortality.

Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL.

Cancer. 2014 Aug 15;120(16):2497-506. doi: 10.1002/cncr.28748. Epub 2014 May 22.

29.

Toward a drug development path that targets metastatic progression in osteosarcoma.

Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton PJ, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Meltzer P, Kirsch DG, Janeway KA, Weigel B, Randall L, Withrow SJ, Paoloni M, Kaplan R, Teicher BA, Seibel NL, Smith M, Uren A, Patel SR, Trent J, Savage SA, Mirabello L, Reinke D, Barkaukas DA, Krailo M, Bernstein M.

Clin Cancer Res. 2014 Aug 15;20(16):4200-9. doi: 10.1158/1078-0432.CCR-13-2574. Epub 2014 May 6.

30.

Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group.

Orgel E, Sposto R, Malvar J, Seibel NL, Ladas E, Gaynon PS, Freyer DR.

J Clin Oncol. 2014 May 1;32(13):1331-7. doi: 10.1200/JCO.2013.52.6962. Epub 2014 Mar 31.

31.

The American society of pediatric hematology/oncology (ASPHO) 2013 distinguished career award goes to Dr. Gregory H. Reaman.

O'Leary MC, Smith FO, Seibel NL.

Pediatr Blood Cancer. 2013 Jun;60(6):897-8. doi: 10.1002/pbc.24528. Epub 2013 Mar 28. No abstract available.

PMID:
23553980
32.

Children, adolescents, and young adults with leukemia: the empty half of the glass is growing.

Bleyer A, Siegel SE, Coccia PF, Stock W, Seibel NL.

J Clin Oncol. 2012 Nov 10;30(32):4037-8; author reply 4038-9. doi: 10.1200/JCO.2012.44.7466. Epub 2012 Oct 1. No abstract available.

PMID:
23032621
33.

Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.

Mattano LA Jr, Devidas M, Nachman JB, Sather HN, Hunger SP, Steinherz PG, Gaynon PS, Seibel NL; Children's Oncology Group.

Lancet Oncol. 2012 Sep;13(9):906-15. Epub 2012 Aug 15.

34.

Outcomes of patients with revised stage I clear cell sarcoma of kidney treated in National Wilms Tumor Studies 1-5.

Kalapurakal JA, Perlman EJ, Seibel NL, Ritchey M, Dome JS, Grundy PE.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):428-31. doi: 10.1016/j.ijrobp.2012.04.023. Epub 2012 Jun 1.

PMID:
22658515
35.

Bilateral synchronous tibial periosteal osteosarcoma with familial incidence.

Maheshwari AV, Jelinek JS, Seibel NL, Meloni-Ehrig AM, Kumar D, Henshaw RM.

Skeletal Radiol. 2012 Aug;41(8):1005-9. doi: 10.1007/s00256-012-1376-7. Epub 2012 Feb 17.

PMID:
22349598
36.

Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group.

Janeway KA, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Ebb DH, Seibel NL, Grier HE, Gorlick R, Marina N.

Cancer. 2012 Sep 15;118(18):4597-605. doi: 10.1002/cncr.27414. Epub 2012 Jan 17.

37.

Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference?

Parsons HM, Harlan LC, Seibel NL, Stevens JL, Keegan TH.

J Clin Oncol. 2011 Oct 20;29(30):4045-53. doi: 10.1200/JCO.2011.36.2954. Epub 2011 Sep 19.

38.

Survival after relapse in childhood acute lymphoblastic leukemia.

Seibel NL.

Clin Adv Hematol Oncol. 2011 Jun;9(6):476-8. No abstract available.

PMID:
21841749
39.

Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group.

Langholz B, Skolnik JM, Barrett JS, Renbarger J, Seibel NL, Zajicek A, Arndt CA.

Pediatr Blood Cancer. 2011 Aug;57(2):252-7. doi: 10.1002/pbc.22882. Epub 2010 Dec 1.

40.

Unique characteristics of adolescent and young adult acute lymphoblastic leukemia, breast cancer, and colon cancer.

Tricoli JV, Seibel NL, Blair DG, Albritton K, Hayes-Lattin B.

J Natl Cancer Inst. 2011 Apr 20;103(8):628-35. doi: 10.1093/jnci/djr094. Epub 2011 Mar 24.

41.

Expanded Access Through Cancer Trials Support Unit to Children's Oncology Group Sarcoma Trial AEWS1031 for Adolescents and Young Adults.

Mascarenhas L, Bond MC, Seibel NL.

J Adolesc Young Adult Oncol. 2011 Mar;1(1):61-3. doi: 10.1089/jayao.2011.1502. No abstract available.

42.

Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group.

Freyer DR, Devidas M, La M, Carroll WL, Gaynon PS, Hunger SP, Seibel NL.

Blood. 2011 Mar 17;117(11):3010-5. doi: 10.1182/blood-2010-07-294678. Epub 2010 Dec 30.

43.

Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV).

Choi MR, Jiles C, Seibel NL.

J Pediatr Hematol Oncol. 2010 Oct;32(7):e268-71. doi: 10.1097/MPH.0b013e3181e5e1af.

PMID:
20736848
44.

Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study.

Gorman MF, Ji L, Ko RH, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon PS, Loh ML.

Pediatr Blood Cancer. 2010 Sep;55(3):421-9. doi: 10.1002/pbc.22612.

PMID:
20658611
45.

Outcomes for children and adolescents with cancer: challenges for the twenty-first century.

Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, Smith FO, Reaman GH.

J Clin Oncol. 2010 May 20;28(15):2625-34. doi: 10.1200/JCO.2009.27.0421. Epub 2010 Apr 19.

46.

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.

Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon PS, Loh ML.

J Clin Oncol. 2010 Feb 1;28(4):648-54. doi: 10.1200/JCO.2009.22.2950. Epub 2009 Oct 19.

47.

Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.

Nachman JB, La MK, Hunger SP, Heerema NA, Gaynon PS, Hastings C, Mattano LA Jr, Sather H, Devidas M, Freyer DR, Steinherz PG, Seibel NL.

J Clin Oncol. 2009 Nov 1;27(31):5189-94. doi: 10.1200/JCO.2008.20.8959. Epub 2009 Oct 5.

48.

Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961.

Withycombe JS, Post-White JE, Meza JL, Hawks RG, Smith LM, Sacks N, Seibel NL.

Pediatr Blood Cancer. 2009 Dec 15;53(7):1249-54. doi: 10.1002/pbc.22237.

49.

Treatment of acute lymphoblastic leukemia in children and adolescents: peaks and pitfalls.

Seibel NL.

Hematology Am Soc Hematol Educ Program. 2008:374-80. doi: 10.1182/asheducation-2008.1.374. Review.

PMID:
19074113
50.

Acute lymphoblastic leukemia: an historical perspective.

Seibel NL.

Hematology Am Soc Hematol Educ Program. 2008:365. doi: 10.1182/asheducation-2008.1.365. No abstract available.

PMID:
19074111

Supplemental Content

Loading ...
Support Center